CAR-T Therapies
Featured Article
True or False: Criteria for inclusion and exclusion in clinical trials of chimeric antigen receptor T-cell therapy for hematologic malignancies are highly variable and bring to light the need for a more standardized approach to patient enrollment.
In a recent case study, CAR-T therapy targeting the CD30 molecule promoted a durable remission in a patient with multiply relapsed enteropathy-associated T-cell lymphoma after previous allogeneic…
Recent research shows that criteria for inclusion and exclusion in clinical trials of CAR‐T therapy for hematologic malignancies are highly variable and bring to light the need for a more…